Seite 1 von 63 Ergebnisse
BACKGROUND OF THE INVENTION
The Yellow Fever virus is endemic, that is, continuously present with low levels of infection in some tropical areas of Africa and the Americas, where it regularly amplifies into epidemics. Other parts of the world, including coastal regions of South America, the
BACKGROUND OF THE INVENTION
The Yellow Fever virus is endemic, that is, continuously present with low levels of infection in some tropical areas of Africa and the Americas, where it regularly amplifies into epidemics. Other parts of the world, including coastal regions of South America, the
FIELD OF THE INVENTION
The invention relates generally to the field of recombinant viruses and induction of specific immunity, specifically to induction of tumor-specific immunity.
BACKGROUND OF THE INVENTION
Tumor-specific cytotoxic T lymphocytes (CTLs) can prevent or eradicate tumors in a number
FIELD OF THE INVENTION
The invention relates generally to the field of recombinant viruses and induction of specific immunity, specifically to induction of tumor-specific immunity.
BACKGROUND OF THE INVENTION
Tumor-specific cytotoxic T lymphocytes (CTLs) can prevent or eradicate tumors in a number
The present invention relates to a vaccine against infections caused by YF virus and its preparation by regenerating YF 17D virus from the correspondent complementary DNA (cDNA) which is present in the new plasmids pYF 5'13' IV/G1/2 and pYFM 5.2/T3/27.
BACKGROUND OF THE INVENTION
The Flavivirus
FIELD OF THE INVENTION
The present invention relates to the use of sulfonyl semicarbazides, semicarbazides and ureas, as well as derivatives and analogs thereof, and pharmaceutical compositions containing the same, for the treatment or prophylaxis of viral infections and diseases associated
FIELD OF THE INVENTION
The present invention relates to the use of sulfonyl semicarbazides, semicarbazides and ureas, as well as derivatives and analogs thereof, and pharmaceutical compositions containing the same, for the treatment or prophylaxis of viral infections and diseases associated
SEQUENCE LISTING
The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Jan. 21, 2011, is named 56441024.txt and is 9,154 bytes in size.
FIELD
The use of sulfonyl
SEQUENCE LISTING
The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Feb. 9, 2011, is named 5644102.txt and is 9,265 bytes in size.
FIELD OF THE INVENTION
The
SEQUENCE LISTING
The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Oct. 12, 2011, is named 56441026.txt and is 7,802 bytes in size.
FIELD
The use of sulfonyl
FIELD OF THE INVENTION
The present invention relates to the use of sulfonyl semicarbazides, semicarbazides and ureas, as well as derivatives and analogs thereof, and pharmaceutical compositions containing the same, for the treatment or prophylaxis of viral infections and diseases associated
FIELD
The use of sulfonyl semicarbazides, carbonyl semicarbazides semicarbazides, and ureas, as well as derivatives and analogs thereof, and pharmaceutical compositions containing the same, for the treatment or prophylaxis of viral infections and diseases associated therewith. In particular, those
FIELD OF THE INVENTION
This invention relates to the use of benzenesulfonamide derivatives and analogs, as well as compositions containing the same, for the treatment or prophylaxis of viral diseases associated with the flavivirus family such as Dengue fever, Yellow fever, West Nile, St. Louis
FIELD OF THE INVENTION
This invention relates to the use of benzenesulfonamide derivatives and analogs, as well as compositions containing the same, for the treatment or prophylaxis of viral diseases associated with the flavivirus family such as Dengue fever, Yellow fever, West Nile, St. Louis
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a National Phase Application of PCT International Application No. PCT/EP2010/065880, International Filing Date, 21 Oct. 2010, claiming priority to European Patent Application No. 09174368.2, filed 28 Oct. 2009, both of which are hereby